References
- Kramer P, Wigger W, Rieger J, Matthaei D, Scheler F. Arteriovenous haemofilteration: A new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin Wochenschr 1997;55:1121-2.
- Ronco C, Brendolan A, Bragantini L, Chiaramonte S, Feriani M, Fabris A, et al. Treatment of acute renal failure in newborns by continuous arteriovenous hemofiltration. Kidney Int 1986;29:908-15. https://doi.org/10.1038/ki.1986.85
- Scott M, Sutherland, Steven R, Alexander. Continuous renal replacement therapy in children. Pediatr Nephrol 2012;27:2007-16. https://doi.org/10.1007/s00467-011-2080-x
- Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 2002;17:61-9. https://doi.org/10.1007/s004670200011
- Vasudevan A, Ivengar A, Phadke K. Modality of choice for renal replacement thepray for children with acute kidney injury: Results of a survey. Indian J Nephrol 2012;22:121-4. https://doi.org/10.4103/0971-4065.97130
- Scott Walters, Craig Porter, Patrick D Brophy. Dialysis and pediatric acute kidney injury: choice of renal support modality. Pediatr Nephrol 2009;24:37-48. https://doi.org/10.1007/s00467-008-0826-x
- Michael Joannidis, Heleen M Oudemnas-van Straaten. Clinical review: Patency of the circuit in continuous renal replacement therapy. Critical Care 2007;11:218. https://doi.org/10.1186/cc5937
- Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail 2012;34:279-85. https://doi.org/10.3109/0886022X.2011.647293
- Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009;31:668-75. https://doi.org/10.3109/08860220903180616
- R.L. Mehta. Anticoagulation in severely ill patients treated with continuous hemofiltration. Nefrologia 1992;12:287-94.
- Hu ZJ, Iwama H, Suzuki R, Kobayashi S, Akutsu I. Time course of activated coagulation time at various site during continuous hemodiafiltration using nafamostat mesilate. Intensive Care Med 1999;25:524-7. https://doi.org/10.1007/s001340050892
- Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H. Matsuda K, Kitamura N. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemidiafiltration. Contrib Nephrol 1991;93:215-7. https://doi.org/10.1159/000420222
- Hiroma T, Nakamura T, Tamura M, Kaneko T, Komiyama A. Continuous venovenous hemofiltration in neonatal onset hyperammonemia. Am J Perinatol 2002;19:221-4. https://doi.org/10.1055/s-2002-28487
- Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009;22:141-5. https://doi.org/10.1111/j.1525-139X.2008.00545.x
- Davis H, Leslie G. Maintaining the CRRT circuit: non-anticoagulant alternatives. Aust Crit Care 2006;19:133-8. https://doi.org/10.1016/S1036-7314(06)80026-3
- Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, et al. Nafamostat mesilate as an anticoagulation during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs 2011;34:571-6. https://doi.org/10.5301/IJAO.2011.8535
- Davenport A. Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments. Pediatr Nephrol 2012;27:1869-79. https://doi.org/10.1007/s00467-012-2129-5
- Nagava M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation-a preliminary report. J Pediatr Surg 1997;32:531-5. https://doi.org/10.1016/S0022-3468(97)90701-6
- Maruyama H, Miykawa Y, Gejyo F, Arakawa M. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. Nephron 1996;74:468-9. https://doi.org/10.1159/000189371
- Higuchi N, Yamazaki H, Kikuchi H, Gejyo F. Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 2000;85:400-1.
- Yamazato M, Mano R, Oshiro-Chinen S, Tomivama N, Sakima A, Ishida A, et al. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialsysis patient. Intern Med 2002;41:864-66. https://doi.org/10.2169/internalmedicine.41.864
- Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol 1995;26:1627-32. https://doi.org/10.1016/0306-3623(95)00072-0
- Ookawara S, Tabei K, Sakurai T, Sakairi Y, Furuya H, Asano Y. Additional mechanisms of nafamostat mesilate-associated hyperkalemia. Eur J Clin Pharmacol 1996;51:149-51. https://doi.org/10.1007/s002280050176
- Kammerl MC, Schaefer RM, Schweda F, Schreiber M, Riegger GA, Kramer BK. Extracorporal therapy with AN 69 membranes in combination with ACE inhibiton causing severe anaphylactoid reactions:still a current problem? Clin Nephrol 2000;53:486-6.
Cited by
- Risk assessment of therapeutic agents under consideration to treat COVID‐19 in paediatric patients and pregnant women vol.87, pp.9, 2014, https://doi.org/10.1111/bcp.14630